In 1Q17, Johnson & Johnson’s (JNJ) Medical Device segment revenues came in at ~$6.3 billion, as compared to $6.1 billion in 1Q16.
On April 18, JNJ released its 1Q17 earnings. After the announcement, the stock fell about 3% from its closing price of $125.72 on April 17.
As of April 21, 2017, there are five analysts tracking Novartis. Of those, two have recommended a “strong buy,” and one has recommended a “buy.”
Sandoz’s revenues are expected to rise in 1Q17 following an increased demand for biopharmaceuticals such as biosimilars and Glatopa.
Analysts expect Alcon’s 1Q17 revenues to fall due to lower equipment sales in the surgical franchise and lower sales in contact lens products.
Analysts expect Novartis’s (NVS) revenues to remain nearly flat at ~$11.7 billion in 1Q17 following the effects of its acquisitions and divestitures.
Novartis’s (NVS) Innovative Medicines segment includes products for therapeutic areas such as oncology, cardiometabolic, immunology, and dermatology.
Novartis is set to release its 1Q17 earnings on April 25, 2017. Analysts estimate its 1Q17 EPS at $1.12 with revenues of ~$11.7 billion.
As we discussed earlier, Johnson & Johnson’s 1Q17 segment-by-segment performance was positive across all of its segments. Now, let’s take a look at some of its major developments during 1Q17.
Johnson & Johnson’s Consumer segment’s revenue rose 1.0% year-over-year to $3.2 billion in 1Q17. This rise included an operational rise of 0.8% and the positive impact of foreign exchange.
Johnson & Johnson’s (JNJ) Medical Devices segment’s revenue rose ~3.0% to ~$6.3 billion in 1Q17 compared to 1Q16. This rise included an operational rise of 3.4%.
Foreign exchange rates have had a constant negative impact on JNJ’s growth rate in each quarter, mainly because nearly 48% of its total revenue is reported from sales outside the United States.
JNJ’s overall business is classified into three segments: Pharmaceuticals, Consumer, and Medical Devices. At constant exchange rates, the company reported growth across all of its segments.
Johnson & Johnson’s (JNJ) Pharmaceuticals segment is made up of the immunology, infectious disease, neuroscience, oncology, and cardiovascular and metabolics franchises.
Johnson & Johnson released its 1Q17 earnings on April 18, 2017, reporting a ~1.6% rise in its top line in 1Q17 compared to 1Q16.
Eli Lilly’s (LLY) animal health segment, Elanco, deals with products for companion animals as well as food and other products.
As of April 19, 2017, there are 22 analysts tracking Eli Lilly. Sixteen of them have recommended a “buy” for the stock.
Eli Lilly’s (LLY) cardiovascular franchise contributes ~15.0% to the company’s total revenues. Key drugs in this segment include Cialis and Effient.
Neuroscience is one of Eli Lilly’s (LLY) franchises in its human pharmaceutical segment. Key drugs in this segment include Zyprexa, Cymbalta, and Strattera.
Eli Lilly’s (LLY) human pharmaceutical segment contributes ~85.0% to Lilly’s total revenues.